Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell over 1% after the drug maker said it would abandon further trials for a potential herpes vaccine after disappointing results from its clinical trials so far.
The FTSE 100 group said data from the phase II part of a proof-of-concept study of the vaccine candidate showed the drug, known as GSK3943104, "did not meet the study's primary efficacy objective".
It therefore will not move the vaccine candidate into phase III studies.
As no safety concerns were observed, the clinical trial, known as TH HSV REC-003, will continue in order to generate follow-up data that could offer valuable insights into recurrent genital herpes, GSK said.
"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed," the company added.